Skip to main
TDOC

Teladoc (TDOC) Stock Forecast & Price Target

Teladoc (TDOC) Analyst Ratings

Based on 15 analyst ratings
Hold
Strong Buy 13%
Buy 13%
Hold 73%
Sell 0%
Strong Sell 0%

Bulls say

Teladoc Health is projected to see slower growth in the BetterHelp segment and a potential decrease in membership, leading to a reduction in revenue. Despite this, their integrated care segment shows promise, and the company has been investing in AI technology, which could lead to long-term success. With their current valuation and solid cost management, there is potential for upward momentum, but the company needs to show stability across all segments for this to occur.

Bears say

Teladoc Health is facing challenges in its transition from a stable, fee-based subscription revenue model to a more volatile visit-based model, leading to uncertainty and a decrease in projected membership. Despite this, Teladoc's virtual care platform and expansion into mental health, chronic care management, and virtual primary care offer long-term growth opportunities. However, these initiatives also require significant investments and there is a risk of pricing pressure and increased competition in the market. To meet its projected revenues and profitability, Teladoc will need to add approximately $36.4M in Integrated Care adjusted EBITDA in CY26, which may require a reduction in stock-based compensation and an increase in tariffs.

Teladoc (TDOC) has been analyzed by 15 analysts, with a consensus rating of Hold. 13% of analysts recommend a Strong Buy, 13% recommend Buy, 73% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Teladoc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Teladoc (TDOC) Forecast

Analysts have given Teladoc (TDOC) a Hold based on their latest research and market trends.

According to 15 analysts, Teladoc (TDOC) has a Hold consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.37, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.37, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Teladoc (TDOC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.